Influenza on cruise ships. by Young, Barnaby E & Wilder-Smith, Annelies
LSHTM Research Online
Young, Barnaby E; Wilder-Smith, Annelies; (2018) Influenza on cruise ships. Journal of travel
medicine, 25 (1). ISSN 1195-1982 DOI: https://doi.org/10.1093/jtm/tay146
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4655348/
DOI: https://doi.org/10.1093/jtm/tay146
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
https://researchonline.lshtm.ac.uk
Influenza on cruise ships 
 
Young B., Wilder-Smith A 
 
Tan Tock Seng Hospital, Department of Infectious Diseases, Singapore 
Lee Kong School of Medicine, Singapore 
London School of Hygiene and Tropical Medicine, United Kingdom 
 
No conflict of interest. 
 
Key words: Influenza; cruise ships; older persons; frailty; influenza vaccines; 
immunosenescence; traveler. 
 
Highlights: 
Influenza outbreaks on cruise ships are of concern. Many cruise ship passengers are of older 
age, and have chronic medical conditions. The response to influenza vaccine declines with 
older age due to changes in the immune system termed immunosenescence. New strategies 
are needed. 
 
Influenza is a common vaccine-preventable infection among travelers.1 All modes of travel 
play a major role in influenza acquisition and the global seeding of new outbreaks to home 
and host countries.2 Cruise ships passengers spend prolonged periods in close quarters, 
facilitating the rapid spread of highly infectious agents such as influenza.  
 
Rogers et al in a recent issue of the Journal of Travel Medicine described two large influenza 
outbreaks among cruise ship passengers and crew.3 On one ship, 3.7% of passengers and 
3.1% of crew had medically attended acute respiratory illness, and on the second ship 6.2% of 
passengers and 4.7% of crew reported a respiratory illness. While influenza activity was low 
at both ships' ports of call, a number of passengers reported recent respiratory illness prior to 
first boarding, suggesting that this was the source of the outbreak.3 Following introduction, 
influenza rapidly spread among crew members and passengers. Similarly, in 2012, a wave of 
influenza B swept a cruise ship sailing off the coast of Sao Paulo, Brazil, and 104 persons 
needed to be hospitalized for acute respiratory illness (ARI), of which 52% were  crew 
members and 49% passengers. One mortality among these patients was caused by post-
influenza Staphylococcus aureus pneumonia.4 Another outbreak of the 2009 pandemic 
A/H1N1 strain and influenza A/H3N2 occurred on a cruise ship in May 2009. Of 1,970 
passengers and 734 crew members, 82 (3.0%) were infected with A/H1N1, 98 (3.6%) with 
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A/H3N2, and 2 (0.1%) with both. Among the 45 children who visited the ship's childcare 
center, the incidence of A/H1N1 infection was even higher.  
 
Influenza infections can become widespread during cruise ship outbreaks and can occur 
outside of traditional temperate-climate influenza seasons. It often leads to an increased use of 
health care services including hospitalization, discontinuation of original travel itineraries and 
incapacitation of essential crew members with interruption in services. The events around the 
2009 A/H1N1 influenza pandemic highlight the need for careful planning to ensure protection 
of those on vessels, at ports of call, and for business continuity. The variety of stakeholders 
involved in the management of a pandemic, and the speed at which it can emerge, hamper 
establishing a cohesive plan during the event itself. 
 
Influenza is preventable with vaccination. Vaccination programs can help to ensure staff have 
received timely vaccines, and pre-cruise advice for passengers should address influenza and 
its prevention, whenever appropriate on the basis of the epidemiological situation concerned. 
Vaccination against influenza should be strongly recommended for travelers at high-risk for 
developing complications, particularly when there has been a recent change in vaccine strain 
composition. The majority of cruise ship tourists are older adults above the age of 55 where 
influenza vaccination should be routinely recommended. In addition, seasonal influenza 
vaccination should be considered for any traveler, regardless of age, wishing to reduce the 
risk of incapacitation.  
 
Several issues need to be addressed with regards to influenza vaccination in cruise ship 
passengers. 
 
Availability of vaccines  
Travelers from temperate regions to the tropics often depart outside of the influenza season. 
As cruise ship vacations are often taken in opposite hemispheres, influenza vaccines covering 
the strains circulating in the opposite hemispheres are needed. However, most Western 
countries often only offer the vaccine strain that was predicted for their hemisphere. Outside 
of the Northern influenza season, influenza vaccines are not available for the Southern 
Hemisphere, and vice versa. Alternate hemisphere and out-of-season influenza vaccine 
availability needs to be enhanced.5  
 
Vaccine refusal 
Vaccine refusal is not infrequent. Refusal of recommended travel-related vaccines among 
U.S. international travelers in Global TravEpiNet showed that of 23 768 eligible travelers, 
6573 (25%) refused one or more recommended vaccine(s). Influenza vaccination was refused 
in 3527 (33%) of 10 539 travelers.6 A lack of concern about the associated illness was the 
most commonly cited reason for all refused vaccines. More effective education about disease 
risk is needed for international travelers, even those who seek pre-travel advice. 
 
Duration of protection after influenza vaccination 
Vaccine effectiveness peaks 2-4 weeks after vaccination, but then declines significantly.7 This 
waning is a concern when timing routine vaccination prior to the annual onset of the ‘flu 
season in temperate climates, but also has important implications for vaccination of travelers 
to tropical countries where influenza circulates throughout the year, or to opposite 
hemispheres when vaccination may have been more than six months prior. Biannual 
vaccination has been suggested to be necessary to provide year-round protection.8 We 
conducted the TROPICS1 study, a randomised clinical trial of six-monthly versus annual 
influenza vaccination. This study aimed to determine if a repeat influenza vaccine at six 
months improves year-round serological measures of protection against influenza in older 
adults.8 Results suggest six-monthly vaccination may be able to overcome issues with 
variation in the timing of epidemics in tropical countries, new vaccine strains between 
hemisphere winters, and waning titres/vaccine effectiveness. An observational study of 
antibody persistence conducted over 2016-17 among older adults in Hong Kong also showed 
that six-monthly vaccination improved protection against circulating seasonal influenza 
strains.9  
 
Older and frail travelers 
Many cruise ship passengers are of older age, and have chronic medical conditions. The 
response to influenza vaccine declines with older age due to changes in the immune system 
termed immunosenescence. This results in both lower antibody titres immediately after 
vaccination, and a significant fall in antibody titres in older adults within six months10, and 
hence accine effectiveness is affected. Adults at more advanced age, frailty, or health-limiting 
co-morbidities are more likely to benefit from six-monthly vaccination.11 Newer vaccines are 
available which improve protection in older adults. This includes vaccines with an immune 
adjuvant (MF-59), a higher dose of virus antigen, or a recombinant antigen which avoids 
some of the issues with viral culture in eggs.12 However, while these vaccines offer improved 
short-term immunogenicity and modest reduction in influenza infection rates, it is not known 
if they will also extend protection beyond a temperate climate winter (eg extend over more 
than 6 months), notwithstanding protection when new antigenic variants emerge between 
hemisphere winters.  
 
Concluding remarks 
Besides advice concerning vaccination, the use of antivirals to interrupt influenza 
transmission needs to be be considered.5 In the report by Rogers et al3, both ships voluntarily 
reported the outbreaks to the CDC and implemented outbreak response plans including 
isolation of sick individuals, early antiviral treatment and prophylaxis. Effective control 
measures to limit influenza transmission on cruise ships are needed to reduce morbidity and 
mortality.  New strategies are required to increase uptake of pre-travel influenza vaccination. 
As many cruise ship travelers are old, often also frail, immune responses to influenza 
vaccination decline, necessitating novel approaches to overcome immunsenescence. Repeat 
influenza vaccination may be required, possibly with better adjuvants, however, potential 
interference in vaccine response with sequential years` vaccination need to be addressed 
before routinely offering 6 monthly re-vaccination.  
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